Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.~2. Age \> 18 years at the time of consent.~3. Karnofsky Performance Status of ≥ 70%.~4. Histological or cytological proof of transitional cell carcinoma of the urothelial tract. The primary site may include: urethra, bladder, ureters, and renal pelvis. Patients with mixed histologies may be enrolled provided that transitional cell carcinoma is the predominant histology.~5. Measurable disease according to RECIST or unresectable disease (cT4b).~6. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.~7. Females of childbearing potential (FCBP)\* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control.~8. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).~9. Adequate organ function as determined by the following laboratory values:~   * Hemoglobin (Hgb) \> 9 g/dL~  * Platelets \> 100 x 1,000,000,000/L~  * Absolute neutrophil count (ANC) \> 1.5 x 1,000,000,000/L~  * Calculated creatinine clearance of \> 60 cc/min using the Cockcroft-Gault formula~  * Bilirubin \< 1.5 x ULN~  * Aspartate aminotransferase (AST, SGOT) \< 1.5 X ULN (\< 5 X ULN if patient has hepatic metastases)~Exclusion Criteria:~1. Has had prior treatment with systemic chemotherapy for metastatic disease (prior intravesical therapy is permitted; prior neoadjuvant/adjuvant chemotherapy permitted if completed ≥ 1 year from study entry)~2. Has received prior lenalidomide.~3. Has had major surgery within 30 days of starting the study treatment~4. Has had any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism~5. Has active CNS metastases. Subjects with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.~6. Has a history of a prior malignancy~7. Has received anticancer therapy, radiation, or any investigational agent within 30 days prior to being registered for protocol therapy.~8. Pregnant or breastfeeding.~9. Has a clinically significant infection as judged by the treating investigator.~10. Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): capsules for oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).